117765-67-0

Basic information

• Product Name: Methyl 2-(N-Methyl-N-phenylsulfaMoyl)acetate
• Synonyms: Methyl 2-(N-Methyl-N-phenylsulfaMoyl)acetate;2-[(methylphenylamino)sulfonyl]Acetic acid methyl ester
• CAS NO: 117765-67-0
• Molecular Formula: C₁₀H₁₃NO₄S
• Molecular Weight: 243.27952
• Mol File: 117765-67-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 2-(N-Methyl-N-phenylsulfaMoyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-(N-Methyl-N-phenylsulfaMoyl)acetate(117765-67-0)
• EPA Substance Registry System: Methyl 2-(N-Methyl-N-phenylsulfaMoyl)acetate(117765-67-0)

Safety Data

• Hazardous Substances Data: 117765-67-0(Hazardous Substances Data)

Upstream product

• 56146-83-9 chlorosulfonyl-acetic acid methyl ester 
• 100-61-8 N-methylaniline 
• 62-53-3 aniline 

Downstream Products

• 957070-16-5 tert-butyl 4-(2-methoxy-1-{[methyl(phenyl)amino]sulfonyl}-2-oxoethyl)benzoate 
• 1136056-58-0 methyl 1-(N-methyl-N-phenylaminosulfonyl)cyclopropanecarboxylate 
• 1001915-87-2 N-methyl-1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo-[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-phenylmethanesulfonamide 
• 1001915-86-1 1-(3-chloro-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl)-N-methyl-N-phenylmethanesulfonamide 
• 1001915-85-0 methyl (3-chloro-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]-pyridin-7-yl)[methyl(phenyl)sulfamoyl]acetate 

Relevant articles and documents

INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5] cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met

This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under investigation as a treatment for cancer. The design of 11r was based on the desire to reduce time-dependent inhibition of CYP3A4 (TDI) by members of this structural class. A novel two-step protocol for the synthesis of benzylic sulfonamides was developed to access 11r and analogues. We provide a rationale for the observed selectivity based on X-ray crystallographic evidence and discuss selectivity trends with additional examples. Importantly, 11r provides full inhibition of tumor growth in a c-Met amplified (GTL-16) subcutaneous tumor xenograft model and may have an advantage over inactive form kinase inhibitors due to equal potency against a panel of oncogenic activating mutations of c-Met in contrast to c-Met inhibitors without preferential binding to the active kinase conformation.

Synthesis of sultams by cycloalkylation of (alkoxycarbonylmethane) sulfonanilides

(Methoxycarbonylmethane)sulfonanilides are alkylated by α, ω-dihaloalkanes in K2CO3-DMF with the formation of sultams. A high sensitivity has been detected for the reaction rate on the electronic effect of substituents in the aromatic nucleus, although substituents in the ortho position do not obstruct the reaction and in the case of 2,6-disubstituted derivatives the reaction rate and sultam yield were maximal. Tertiary sulfonamides form derivatives of 1-sulfamoylcyclopropanecarboxylic acid under these conditions.